A study out today in Lancet Respiratory Medicine examines whether an experimental drug known as Fevipiprant could help adults with severe asthma.

Dr. Bob Lanier, Executive Medical Director for the American College of Allergy, Asthma and Immunology (ACAAI) is an expert on the drug, and can speak to its properties.

A past ACAAI president, Dr. Lanier is a practicing allergist in Texas and has done clinical studies with the drug. He is available for interviews on the topic.